Navigation Links
Large-Scale Global Registry to Examine Treatment Patterns and Disease Burden Among Patients with Venous Thromboembolism (VTE)
Date:9/3/2013

AMSTERDAM, Sept. 3, 2013 /PRNewswire/ -- The Thrombosis Research Institute (TRI) today announced the launch of the GARFIELD (Global Anticoagulant Registry in the FIELD) VTE Registry, an innovative research initiative exploring acute and long-term management and outcomes in patients with symptomatic venous thromboembolism (VTE).  Led by an international steering committee under the auspices of the TRI, the registry will follow 10,000 patients with acute VTE in a real-world setting.  GARFIELD VTE is supported by an unrestricted research grant from Bayer HealthCare.

VTE is a disease process that encompasses two interrelated conditions: deep vein thrombosis (DVT), in which a blood clot forms in a deep vein such as the legs, and pulmonary embolism (PE), a life-threatening condition in which part of the clot breaks off and is carried to the lungs through the heart, cutting off the flow of blood to the lungs.  In the Western world, one person dies every 37 seconds from VTE.

"Venous thromboembolism continues to represent an important clinical challenge, with a heavy burden for patients and healthcare systems," said Professor The Lord Kakkar, Professor of Surgery at University College London and Director of the Thrombosis Research Institute, London, UK. "Better understanding how best patient outcomes can be achieved will be greatly assisted through robust outcomes research.  We are grateful for the unrestricted grant from Bayer Healthcare to support the Garfield VTE Registry which builds on our experience in better understanding the real world challenges of providing anticoagulation to prevent thromboembolic stroke in the Garfield AF Registry."

About GARFIELD
GARFIELD is a pioneering outcomes research initiative led under the auspices of the TRI through an unrestricted research grant from Bayer HealthCare.  It is comprised of two large-scale registries: GARFIELD AF and GARFIELD VTE.  The real-world, global observational programme seeks to describe the real-life burden of these diseases, and provide a better understanding of antithrombotic treatment patterns and potential opportunities for improving care and clinical outcomes. 

GARFIELD AF (atrial fibrillation) is the largest prospective registry of patients with AF at risk of stroke.  It will prospectively follow 50,000 newly-diagnosed AF patients from at least 1,000 centres in 34 countries in the Americas, Eastern and Western Europe, Asia, Africa and Australia.  Results to date show that anticoagulant therapy, particularly vitamin K antagonists (VKA), which are known to prevent stroke, are underutilised in AF patients who are at high risk for stroke while at the same time being over-used in low-risk patients.

GARFIELD VTE will include 10,000 patients with acute VTE and indicated for anticoagulation, across 500 randomly selected sites, from 20-25 countries over four years.  The registry will focus on treatment duration, incidence of complications, practical aspects and health economic and outcomes research.

About the Thrombosis Research Institute (TRI)
TRI is a charitable foundation and multi-disciplinary research institute dedicated to the study of thrombosis and related disorders. TRI's mission is to provide excellence in thrombosis research and education; to develop new strategies to prevent and treat thrombosis; and thereby improve quality of care, advance clinical outcomes and reduce healthcare costs. The TRI is a member of University College London Partners Academic Health Science System.

For more information, visit http://www.tri-london.ac.uk/garfield.


'/>"/>
SOURCE Thrombosis Research Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Large-Scale Kaiser Permanente Program Linked to Improved Blood Pressure Control
2. First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams
3. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
4. Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
5. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
6. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
7. PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
8. Peripheral Vascular Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
9. Philips launches new EPIQ premium ultrasound system with first-of-its-kind nSIGHT technology and Anatomical Intelligence, to address complicated imaging needs of an aging global population
10. MEMS in Medical Applications Market is Expected to Reach USD 6.5 Billion Globally in 2019: Transparency Market Research
11. Injectable Dose Formulations Highly Impact Global Pharmaceutical Contract Manufacturing Vendor Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... responds to and which He does not. Yisrayl says with so many titles and ... true name, but he says with a little Scripture, backed with a lot of research, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Rob Lowe is ... now he has leant his presence to an educational purpose as the host of ... important one being cancer. In a recent episode, the series focuses on thyroid cancer. ...
Breaking Medicine News(10 mins):